2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Conditions
HIV Infections
2
Sarcoma, Kaposi
1
Lymphoma, AIDS-Related
1
Dendritic Cell Sarcoma, Interdigitating
1
Acquired Immunodeficiency Syndrome
1
Interventions
Cyclophosphamide
76
fludarabine phosphate
42
Filgrastim
38
Peripheral Blood Stem Cell Transplantation
35
Radiotherapy
33
Cyclosporine
32
Busulfan
32
Mycophenolic Acid
30
Etoposide
30
Antilymphocyte Serum
28
Whole-Body Irradiation
26
Methotrexate
25
Rituximab
22
Melphalan
21
Methylprednisolone
20
Vincristine
17
Tacrolimus
17
Cytarabine
17
Cord Blood Stem Cell Transplantation
17
Doxorubicin
16
Prednisone
15
Thiotepa
10
Granulocyte Colony-Stimulating Factor
9
Carboplatin
8
Leucovorin
7
fludarabine
6
aldesleukin
6
Ifosfamide
6
sargramostim
5
Sirolimus
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Dendritic Cell Sarcoma, Interdigitating
×
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
×
Clear all
NCT00799136
2013-09-12
CATCH
Ontario Clinical Oncology Group (OCOG)
Phase 2
Completed
6 enrolled